Back to Journals » Biologics: Targets and Therapy » Volume 5

An update on belimumab for the treatment of lupus

Authors Thanou-Stavraki A, Sawalha A

Published 14 February 2011 Volume 2011:5 Pages 33—43

DOI https://doi.org/10.2147/BTT.S13804

Review by Single-blind

Peer reviewer comments 2

Aikaterini Thanou-Stavraki1, Amr H Sawalha1,2,3
1Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; 2US Department of Veterans Affairs Medical Center, Oklahoma City, OK, USA; 3Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA

Abstract: B-lymphocyte stimulator (BLyS), a homeostatic factor for B-cell differentiation and survival, has a major role in B-cell expansion and autoreactivity that characterize systemic lupus erythematosus (SLE). Belimumab, a BLyS-specific inhibitor, has shown promising evidence of efficacy in several preclinical and clinical studies in SLE. Two recent large randomized controlled trials yielded a significant positive effect of the drug compared to placebo in patients with active disease. In this review, we discuss basic aspects of B-cell and BLyS biology in SLE and summarize the evidence supporting a role of belimumab in SLE, from animal studies to phase III clinical trials.

Keywords: B lymphocyte stimulator, lupus erythematosus, belimumab

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]